ORIGINAL INVESTIGATION. Limb Fractures in Elderly Men as Indicators of Subsequent Fracture Risk

Size: px
Start display at page:

Download "ORIGINAL INVESTIGATION. Limb Fractures in Elderly Men as Indicators of Subsequent Fracture Risk"

Transcription

1 ORIGINAL INVESTIGATION Limb Fractures in Elderly Men as Indicators of Subsequent Fracture Risk Bruce Ettinger, MD; G. Thomas Ray, MBA; Alice R. Pressman, MS; Oscar Gluck, MD Background: Whether limb fracture in elderly men predicts future fracture is unknown. Methods: Electronic health records were examined to determine fracture incidence among men 60 years or older who were members of a large health maintenance organization, experienced no fracture in the past 2 years, and experienced an ankle, hip, humerus, or wrist fracture between July 1, 1997, and August 31, Proportional hazards models were used to compare risk of new fracture (ankle, hip, humerus, or wrist) between groups. Recurrent fractures of the same type were excluded from analysis. Results: During the follow-up period (mean duration, 2.4 years), 0.5% of the control subjects without fractures experienced a subsequent ankle fracture; 0.6%, a hip fracture; 0.2%, a humerus fracture; and 0.4%, a wrist fracture. A limb fracture was about 4 times more likely to occur in persons who experienced a previous humerus fracture (relative risk, 3.9; 95% confidence interval, ), about 3 times more likely to occur in persons who experienced a previous hip fracture (relative risk, 2.8; 95% confidence interval, ), and about 2 times more likely to occur in persons who experienced a previous wrist fracture (relative risk, 2.2; 95% confidence interval, ) than in controls. In contrast, persons who experienced a previous ankle fracture had no greater risk of subsequent fracture than nonfracture controls (relative risk, 1.0; 95% confidence interval, ). Conclusions: Among men 60 years or older, a recent hip, humerus, or wrist fracture is a statistically and clinically significant predictor of future limb fracture risk. An increased risk of future fracture is greatest after a humerus fracture and is lowest after a wrist fracture; however, among elderly men, a previous ankle fracture is not an indicator of future fracture risk. Arch Intern Med. 2003;163: From the Division of Research, Kaiser Permanente Medical Care Program, Oakland, Calif (Dr Ettinger, Mr Ray, and Ms Pressman); and the Arizona Rheumatology Center, Phoenix (Dr Gluck). The authors have no relevant financial interest in this article. RISK FACTORS related to osteoporotic fracture in women have been extensively investigated, but the epidemiologic features of osteoporotic fracture in men have received attention only recently. Fracture among aging men is a clinically significant health problem, as indicated by the fact that about one third of all fractures among elderly persons occur in men. 1,2 The lifetime risk of fragility fracture among white men at the age of 60 years has been estimated at 21% in England and Wales 1 and at 15% in Australia. 2 Fracture in men results in clinically significant morbidity, mortality, and cost to society. 3,4 Among people older than 75 years, the hip fracture related mortality rate is higher in men than in women, probably for reasons related to greater incidence of comorbid conditions among aging men than among similarly aged women. 5 Given the magnitude of the fracture risk among aging men, programs aimed at preventing osteoporotic fracture should receive greater emphasis. Identifying persons at risk for future fracture is a key part of any prevention program. Several clinical risk factors for fracture are related to falls and frailty and seem to operate similarly in men and women. 6,7 Low bone density 6,8-10 and the results of serum biochemical tests 6 have also been shown to predict fracture risk similarly in both sexes. The previous occurrence of fracture can be determined during patient visits or from administrative electronic databases available to governmental and managed care organizations. Such data could be used to identify patients at increased risk for osteoporotic fracture and could lead to appropriate use of interventions to reduce the number of fractures in populations at high risk. Although the association between fracture occurrence and future fracture risk has been adequately studied in women, this 2741

2 A Men Aged 60 y With a Potential Index Fracture of the Ankle, Hip, Humerus, or Wrist (n = 4256) B Men Aged 60 y With a Potential Index Fracture of the Finger (n = 983) Membership Exclusion (n = 520) Membership Exclusion (n = 124) >24 mo of Continuous Health Plan Membership (n = 3736) >24 mo of Continuous Health Plan Membership (n = 859) Pathologic Fracture (n = 46) Pathologic Fracture (n = 2) Eligible (n = 3690) Eligible (n = 857) Ankle Fracture (n = 1087) Hip Fracture (n = 1175) Humerus Fracture (n = 486) Wrist Fracture (n = 942) Finger Fracture (n = 857) (n = 20) (n = 61) (n = 16) (n = 17) (n = 16) Ankle Fracture (n = 1067) Hip Fracture (n = 1114) Humerus Fracture (n = 470) Wrist Fracture (n = 925) Finger Fracture (n = 841) Figure 1. Selection of patients with an index fracture of the ankle, hip, humerus, or wrist (A) or an index fracture of the finger (B). The asterisk indicates a health plan member for less than 24 months; dagger, excluded because of health conditions or drugs. association in men requires further elucidation. A metaanalysis 11 of 34 studies published through September 1999 concluded that previous fracture approximately doubled the risk of future fracture in men and women; the researchers commented on the uniformity of risk between sexes and for various fracture sites. However, this summary of 34 good-quality studies contained only 4 studies designed to examine fracture risk in men and 4 other studies that yielded usable information on fracture risk in men after studying both sexes. Thus, a need exists for data on fracture risk after various types of fracture in aging men and on the strength of associations for different types of limb fracture. We hypothesized that limb fracture would signal increased skeletal fragility and, thus, increased risk of future osteoporotic fracture. Therefore, we studied the associations between 4 limb fractures considered osteoporotic and the subsequent risk of similar fracture among elderly men. The database for members of a large health maintenance organization was analyzed to compare the risk of subsequent fracture among men with each of these 4 sites of index fracture with the risk among men without such a history. The analysis included adjustment for clinical confounders related to frailty and falling. METHODS SETTING The Kaiser Permanente Medical Care Program is an integrated, group-model, nonprofit health maintenance organization serving approximately 3 million members throughout Northern California. The Kaiser Permanente Northern California Institutional Review Board approved the study protocol. SOURCES OF FRACTURE DIAGNOSIS DATA Kaiser Permanente hospital diagnoses were extracted from the health plan s Admission Discharge and Transfer system, in which are maintained records for all hospital encounters (inpatient and ambulatory surgery) and all associated diagnoses. Diagnoses for emergency department visits and office visits were extracted from Kaiser Permanente s Outpatient Summary Clinical Record. At each visit, physicians and nurse practitioners select from relevant diagnoses listed in specialty-specific forms; diagnoses checked off on these forms populate the Outpatient Summary Clinical Record database. Diagnoses for episodes of hospitalization and for emergency claims made at non Kaiser Permanente sites were extracted from the Outside Medical Services systems, which capture diagnostic information included on billing statements. IDENTIFICATION OF THE FRACTURE AND COMPARISON COHORTS The evolution of our study cohort is depicted in Figure 1.From our automated databases, we extracted all cases of fracture diagnosed in men between July 1, 1995, and August 31, By using these data, we identified all closed fractures of the ankle (talus or distal tibia), hip (proximal femur), humerus, or wrist (Figure 1A). We assumed that a true hip fracture would have resulted in a hospitalization; thus, to exclude spurious diagnoses, we required that hip fracture be identified from inpatient hospital stays. Similarly, we required that an ankle, humerus, or wrist fracture be diagnosed either in an orthopedics department or at a second visit for the same fracture within 60 days after the initial fracture event. The study included only men 60 years or older at the index fracture. The index fracture was defined as the first nonpathologic fracture of the ankle, hip, humerus, or wrist not preceded by any fracture of any kind during the preceding 2 years. To ensure a minimum 2 years of prior 2742

3 observation, we required that subjects be members of the health plan continuously during the 2 years before the index fracture. Patients who had multiple fractures occurring on the same day were excluded from the analysis to preclude the possibility of miscoding as a new fracture one that occurred concurrently with an index fracture. We also excluded from analysis persons with a history of pathologic fractures occurring before the index date. Pathologic fractures were identified by International Classification of Diseases, Ninth Revision (ICD-9) code. The primary comparison group was randomly selected from all men who were 60 years or older on January 1, 1999, and who had continuous health plan membership but no fracture of any kind during the previous 2 years (Figure 2). The index date for these men was January 1, A second comparison group was composed of men who sustained a closed finger fracture (Figure 1B). This group was selected using the same inclusion and exclusion criteria as used for the 4 limb fracture groups, but because a closed fracture of the finger rarely requires multiple visits or a visit to an orthopedist, a single diagnosis from any source was considered sufficient for selection of the second comparison group. Among the fracture and comparison cohorts, we excluded persons who, before the index date, received treatment known to affect risk of osteoporosis. Therefore, we excluded 3 groups of men: those diagnosed as having Paget disease, those who used the equivalent of 2 g or more ofprednisone-equivalent glucocorticoid agents in the year before the index date, and those who used osteoporosis prevention related drugs (alendronate sodium, calcitonin, etidronate disodium, or risedronate sodium) during the year before the index date. The level of prednisone equivalent was chosen because intake of 5 mg/d or more for more than 3 months is considered by experts a level of use likely to increase the risk of osteoporotic fracture. 20 Our final cohort consisted of 3576 men 60 years or older with an index fracture as defined for this study in the following areas: ankle (n=1067), hip (n=1114), humerus (n=470), and wrist (n=925). The comparison group with a finger fracture consisted of 841 men, and the nonfracture comparison group consisted of men, of whom (about half the sample) were randomly selected for study. IDENTIFICATION OF SUBSEQUENT FRACTURES For men in the fracture and nonfracture groups, we identified ankle, hip, humerus, and wrist fractures that occurred after the index dates. Follow-up from the index date ended when 1 of 4 conditions was met: (1) the first ankle, hip, humerus, or wrist fracture was sustained; (2) health plan membership was discontinued; (3) death; or (4) the end of the study period was reached (August 31, 2001). Without examining written medical records, we could not always distinguish between continuing care for a fracture and a new fracture of the same type; therefore, we considered only subsequent fractures that differed in site from the index fracture. For example, for men who had an index hip fracture, only a subsequent ankle, humerus, or wrist fracture counted as an event; subsequent diagnoses of hip fracture were ignored. REVIEW AND VERIFICATION OF SUBSEQUENT FRACTURES Men Aged 60 y >24 mo of Continuous Health Plan Membership Before 1/1/1999 Fracture Exclusion (n = 6962) (n = 985) >24 mo Without a Fracture (n = ) Eligible (n = ) About 50% Random Sample (n = ) Figure 2. Selection of patients in the control group without fractures. The asterisk indicates fracture of any kind before January 1, 1999; dagger, excluded because of health conditions or drugs. One of us (B.E.) reviewed the radiographic reports of all men with an index fracture who subsequently had a new fracture during the study period. Cases were excluded if electronically available radiology reports failed to confirm a subsequent fracture or if the presumed subsequent fracture was, in fact, concurrent with the index fracture but had not been included in the Outpatient Summary Clinical Record or the Admission Discharge and Transfer system until a later time. Most cases of incorrect coding of a presumed subsequent fracture were because of continuing care for the index fracture and seemed to be caused by physicians or nurse practitioners inadvertently checking a different fracture type on the Outpatient Summary Clinical Record diagnosis form. Therefore, errors of this type were associated with the index fracture, and we did not expect to find them for the comparison group with no index fracture. ANALYSIS We used a separate proportional hazards model to estimate the increased hazard of a subsequent fracture for each index fracture type. The outcome of interest was the first fracture after the index date. Data for any person were censored if the person died or otherwise discontinued health plan membership before the end of follow-up. Separate models compared persons with each type of index fracture with persons who had no previous fracture and with persons whose index fracture was of the finger. Because our analysis excluded subsequent fractures of the same site as the index fracture, the same fracture was necessarily excluded as an outcome in the nonfracture and finger fracture comparison groups. Thus, for example, a person in the nonfracture comparison group who had a hip fracture on March 1, 2000, and an ankle fracture on August 1, 2000, was counted as having an ankle fracture when compared with men who had an index hip fracture and was counted as having a hip fracture when compared with men who had an index ankle fracture. All proportional hazards models were adjusted for the following factors: (1) age, (2) cardiac-related drug use, (3) central nervous system related drug use, (4) diabetes mellitus related drug use, (5) hospitalizations, and (6) office visits. Each drug use variable was modeled dichotomously and refers to any use in the year before the index fracture. Hospitalization and visit counts were each modeled as a continuous variable and were measured in the 395 to 30 days before the index fracture. When deriving hospitalization and office visit measures, we excluded the period 30 days before the index date so as not to include health care use that might have been associated with the fracture event. 2743

4 Table 1. Characteristics of Male Patients 60 Years or Older With an Index Fracture and a Comparison Group With No Index Fracture* Characteristic Ankle (n = 1067) Group With an Initial Index Fracture Hip (n = 1114) Baseline Data Humerus (n = 470) Wrist (n = 925) Finger (n = 841) Comparison Group With No Index Fracture (N = ) Age group at the index date, y Age at the index date, mean, y Health status related variables used as covariates Hospitalization between 395 and 30 d before the index date, mean Office visits between 395 and 30 d before the index date, mean Cardiac-related drug prescribed in the year before the index date Active central nervous system related drug prescribed in the year before the index date Diabetes mellitus related drug prescribed in the year before the index date Follow-up Data Died before the end of follow-up Length of follow-up, mean, mo Fracture occurred after the index date Subsequent fracture of the hip, humerus, 0.8 NA NA NA or wrist Subsequent fracture of the ankle, humerus, NA 2.0 NA NA or wrist Subsequent fracture of the ankle, hip, NA NA 5.1 NA or wrist Subsequent fracture of the ankle, hip, or humerus NA NA NA Abbreviation: NA, data not applicable. *Data are given as percentage of each group unless otherwise indicated. Data are from the Kaiser Permanente Medical Care Program, Oakland, Calif, from July 1, 1997, through August 31, Percentages may not total 100 because of rounding. P.05 vs persons with no index fracture, unadjusted. Calculated only for persons who did not have a fracture after the index date; for those who did have a fracture after the index date, follow-up ended when the fracture occurred. For persons with an index fracture of the ankle, hip, humerus, or wrist, outcome at a site other than the index fracture site. For persons with an index fracture of the finger or for those who were in the nonfracture comparison group, the outcome fracture site was matched with the site used for the fracture comparison group. RESULTS PATIENT CHARACTERISTICS AND UNADJUSTED ANALYSES On average, men who had an index ankle, hip, humerus, or wrist fracture differed from each other and from men in the nonfracture comparison group. Men with a limb fracture tended to be older than men without an index fracture, had more hospitalizations and outpatient visits, and were more likely to have received a prescription for one of the high-risk drugs (Table 1). More men with an index hip or humerus fracture died during follow-up compared with men without an index fracture. When follow-up was calculated for persons who did not have a subsequent fracture (because follow-up artificially ended for them at that point), follow-up ranged from 15 to 23 months for persons with an index fracture but was 29 months for men without an index fracture. This difference was in part explained by a higher mortality rate among some of the fracture groups (particularly those with a hip or humerus fracture) but was also due to the study chronology. Follow-up for the nonfracture group began on January 1, 1999, whereas follow-up for patients with an index fracture started at a later date (ie, when the index fracture occurred). Figure 3 shows the proportions of these groups who were free from fracture over time; the hazard function was linear for all types of fracture, and no excessive risk was observed during the early months after the index fracture occurred. The proportion of men with 1 or more subsequent fractures of a type different from that of the index fracture was higher for men after an index fracture of the hip (2.0%), humerus (5.1%), or wrist (2.5%) than for men who had a similar fracture outcome but no index fracture. Among those men, a subsequent fracture at a different location occurred in 1.1% of those who previously had a hip fracture, 1.5% of those who previously 2744

5 1.00 A B Probability of No Subsequent Fracture Ankle Fracture Group Hip Fracture Group Probability of No Subsequent Fracture C Humerus Fracture Group Follow-up, mo D Wrist Fracture Group Follow-up, mo Figure 3. Probability of remaining free of fracture during follow-up by type of index fracture. A, Ankle fracture. B, Hip fracture. C, Humerus fracture. D, Wrist fracture. Table 2. Hazard Ratios of Incurring a Subsequent Fracture for Male Patients 60 Years or Older With an Initial Fracture of the Ankle, Hip, Humerus, or Wrist Compared With Persons Who Had an Initial Fracture of the Finger and Persons in the, After Adjustment* Type of Initial Fracture Compared With the Hazard Ratio (95% Confidence Interval) Compared With the Finger Fracture Group Age Adjusted Only All Adjustments Age Adjusted Only All Adjustments Ankle 1.0 ( ) 1.0 ( ) 1.0 ( ) 1.0 ( ) Hip 2.5 ( ) 2.8 ( ) 2.5 ( ) 2.6 ( ) Humerus 4.1 ( ) 3.9 ( ) 3.6 ( ) 3.5 ( ) Wrist 2.2 ( ) 2.2 ( ) 1.7 ( ) 1.7 ( ) *Data are given only for a subsequent fracture of a form different than that of the initial fracture. Data are from the Kaiser Permanente Medical Care Program, Oakland, Calif, from July 1, 1997, through August 31, Proportional hazard models were adjusted for (1) age, (2) cardiac-related drug use, (3) central nervous system related drug use, (4) diabetes mellitus related drug use, (5) hospitalizations, and (6) office visits. Each drug use variable was modeled dichotomously, and is based on use in the year before the index date. Hospitalization and visit counts were each modeled as a continuous variable, and were measured in the 395 to 30 days before the date of the index fracture. P.05. had a humerus fracture, and 1.3% of those who previously had a wrist fracture. These results, however, are based on differing lengths of follow-up and on differing baseline risk factors. ADJUSTED HAZARD RATES OF SUBSEQUENT FRACTURES After adjusting for follow-up time, age of the patient, and baseline measures of health status, a subsequent fracture was more likely to occur in men with an index hip, humerus, or wrist fracture than in men who had either no fracture or an index fracture of the finger (Table 2). Compared with men who had no index fracture, men with an index fracture of the humerus were nearly 4 times more likely to have a subsequent nonhumerus fracture (ankle, hip, or wrist). Compared with men who had no index fracture, men with an index fracture of the hip were about 3 times more likely to have a subsequent fracture, and men with an index fracture of the wrist were about 2 times 2745

6 more likely to have a subsequent fracture. In contrast to men with a history of these sites of limb fracture, men with an index fracture of the ankle had no greater risk of subsequent fracture than men in the nonfracture control group. When the ankle, hip, humerus, and wrist fracture cohorts were compared with those who had an index fracture of the finger, results were similar. Men with a fracture of the humerus or hip were still more likely to have a subsequent fracture, although the hazard ratios for this group were somewhat lower and the confidence intervals were wider. Men with a wrist fracture were also more likely to have a subsequent fracture than those with an index fracture of the finger, but this difference was not statistically significant (P=.13). COMMENT In our study of aging men, we found a strong association between a hip, humerus, or wrist fracture and the risk of a subsequent fracture, but this association did not exist for an ankle fracture. Compared with either men who had no recent fracture or men with an index fracture of the finger, men in our study who had a previous humerus, hip, or wrist fracture were about 2- to 3-fold more likely to have a subsequent limb fracture. A recent summary 11 of 34 studies found a 2- to 3-fold increase in the risk of a subsequent fracture for both sexes. Most published studies on the subject have reported an association in women or in men and women, but relatively few men were studied. These studies focused primarily on a fracture of the hip or spine. Compared with community-derived fracture rates, 243 men 35 years or older in Rochester, Minn, who had an index wrist fracture had a 2.7-fold greater risk of a subsequent hip fracture. 17 A similar epidemiologic study 16 of fracture rates among 212 Swedish men 40 years or older who had an index wrist fracture compared this group against a population registry of men free of fracture and found a relative risk (RR) of 2.3 of subsequent hip fracture in the study group. In cohort studies 12,13 of aging men, the RR of prior fracture was estimated after multiple statistical adjustments, including an adjustment for bone mineral density. A study 13 of 654 Swedish men compared those with and without a previous fracture and found that 82 men with a previous wrist fracture had an RR of 1.8 of a subsequent fragility fracture of the vertebra, wrist, humerus, pelvis, tibia, or hip, whereas 39 men with a previous hip fracture had a 1.6-fold higher RR (neither RR was statistically significant). Another similar cohort study 12 of men 60 years or older living in Australia found that those with a history of nontraumatic or lowtrauma fracture in the previous 5 years had a 1.4-fold increased risk of subsequent nontraumatic or low-trauma fracture during a 5-year follow-up period. In a study 19 designed to examine the risk of recurrent hip fracture, men with a previous hip fracture had an RR of 3.2 of a subsequent hip fracture. Beyond hip and wrist fracture data, to our knowledge, predictive values of other specific limb fractures have not been described in men. In our study, an ankle fracture among aging men was not associated with a subsequent limb fracture. And unlike the strong age-related relation we observed between hip and humerus fractures, we did not find any age-related increase in the rate of ankle fracture among men at our health maintenance organization. Other researchers have suggested that ankle fractures may not indicate osteoporosis. Lauritzen and Lund 21 failed to find a statistically significant association between ankle fracture and subsequent hip fracture in women. In that study, 21 elbow and knee fractures showed a statistically significant association with hip fracture. Moreover, an ankle fracture in women does not show the usual relation to age and bone mineral density 22,23 seen for other fragility fractures. A major strength of our report is its large sample size, which included hundreds of fractures of each type. In addition, we were able to validate all fracture outcomes among persons with an index limb fracture. We also were able to adjust for measures of medical use, general health status, and prescription use, which we interpreted (from existing medical literature) to be related to falls or to low bone mineral density. Certain drugs are associated with a high risk of dizziness, a condition that may lead to falls and, therefore, to fracture. The risk of falls and fracture may be increased about 2-fold in persons who use psychoactive medications, including antidepressant agents 24 and benzodiazepine drugs. 25 However, we found that adjusting for these health conditions and medications did not consistently reduce the strength of the association between fracture and subsequent fracture, perhaps because the index fracture variable subsumed factors relating to frailty and falls. A limitation of our study was that we did not validate fracture outcome in the large group of nonfracture controls. This omission could produce a conservative bias because possible incident fracture was removed from the limb fracture groups but not from the nonfracture controls. In addition, we found it necessary to examine only fractures differing from the index fracture because of the difficulty in distinguishing between continuing care for the original fracture and care for a new fracture of the same type; this problem is especially difficult during examination of a hip fracture, a condition for which the expected annual rate of readmission for initial fracture (about 10%) is considerably higher than the risk of new hip fracture (about 1%). Another limitation of our study was its relatively short follow-up period, which was mandated by the availability of historical data in our database; however, a linear hazard function constructed for patients in the study suggests that the RR remains stable for 1 to 2 years. Our study was limited to limb fracture because we were unable to adequately document cases of incident vertebral fracture treated at our health maintenance organization. Postmenopausal women with a recent vertebral deformity are well known to be at substantial risk for subsequent fracture, especially in other vertebrae. 26 However, only about 1 in 4 vertebral deformities observed radiologically will manifest clinically as fracture events, 27 and a diagnosis of spinal fracture is frequently overlooked by those reading radiographs in the clinical setting. 28 Moreover, among hospitalized women 60 years or older in whom radiographs showed moderate to se- 2746

7 vere vertebral deformity, only 8% had this diagnosis noted at discharge from the hospital. 28 Thus, unless patients with a vertebral deformity are carefully scrutinized, this condition will not be discovered by clinicians or included in administrative databases. This fact is true of our health plan also and was the reason for our exclusion of spinal fractures from the present epidemiologic study. A prospective study 29 of vertebral deformity in men and women based on radiologic assessment has been performed. We conclude that among elderly men, a recent history of a humerus, hip, or wrist fracture is a statistically significant and clinically relevant predictor of future osteoporotic fracture risk but that a previous ankle fracture is not. Use of fracture history can provide a simple way to identify patients at increased risk for future fracture. Further definition of future fracture risk could be based on other clinical risk factors and on bone density. Identification and risk assessment could ultimately lead to more appropriate use of fracture risk reduction strategies, including medication. Bisphosphonates 30 and parathyroid hormone 31 have enhanced bone mineral density in men and hold promise for reducing the risk of subsequent fracture in men. Other types of interventions designed to reduce fracture risk calcium with vitamin D 32 or use of hip protectors 33 have proved as effective in men as in women. Thus, programs aimed at identifying men with limb fractures may provide a simple low-cost means of focused fracture prevention in these high-risk, but frequently overlooked, patients. Accepted for publication January 24, This study was supported by an unrestricted educational grant from Merck & Co, Inc, West Point, Pa. We thank the Medical Editing Department, Kaiser Foundation Research Institute, Oakland, Calif, for editorial assistance. Corresponding author: Bruce Ettinger, MD, Division of Research, Kaiser Permanente Medical Care Program, 3505 Broadway, Oakland, CA ( bxe@dor.kaiser.org). REFERENCES 1. Van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone. 2001;29: Jones G, Nguyen T, Sambrook PN, Kelly PJ, Gilbert C, Eisman JA. Symptomatic fracture incidence in elderly men and women: the Dubbo Osteoporosis Epidemiology Study (DOES). Osteoporos Int. 1994;4: Randell A, Sambrook PN, Nguyen TV, et al. Direct clinical and welfare costs of osteoporotic fractures in elderly men and women. Osteoporos Int. 1995;5: Poór G, Atkinson EJ, Lewallen DG, O Fallon WM, Melton LJ 3rd. Age-related hip fractures in men: clinical spectrum and short-term outcomes. Osteoporos Int. 1995;5: Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet. 1999;353: Center JR, Nguyen TV, Sambrook PN, Eisman JA. Hormonal and biochemical parameters and osteoporotic fractures in elderly men. J Bone Miner Res. 2000; 15: Tromp AM, Smit JH, Deeg DJ, Bouter LM, Lips P. Predictors for falls and fractures in the Longitudinal Aging Study Amsterdam. J Bone Miner Res. 1998;13: Melton LJ 3rd, Atkinson EJ, O Connor MK, O Fallon WM, Riggs BL. Bone density and fracture risk in men. J Bone Miner Res. 1998;13: Nyquist F, Gärdsell P, Sernbo I, Jeppsson JO, Johnell O. Assessment of sex hormones and bone mineral density in relation to occurrence of fracture in men: a prospective population-based study. Bone. 1998;22: De Laet CE, Van Hout BA, Burger H, Weel AE, Hofman A, Pols HA. Hip fracture prediction in elderly men and women: validation in the Rotterdam Study. J Bone Miner Res. 1998;13: Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15: Nguyen TV, Eisman JA, Kelly PJ, Sambrook PN. Risk factors for osteoporotic fractures in elderly men. Am J Epidemiol. 1996;144: Gärdsell P, Johnell O, Nilsson BE. The predictive value of forearm bone mineral content measurements in men. Bone. 1990;11: Mussolino ME, Looker AC, Madans JH, Langlois JA, Orwoll ES. Risk factors for hip fracture in white men: the NHANES I Epidemiologic Follow-up Study. J Bone Miner Res. 1998;13: Poór G, Atkinson EJ, O Fallon WM, Melton LJ 3rd. Predictors of hip fractures in elderly men. J Bone Miner Res. 1995;10: Mallmin H, Ljunghall S, Persson I, Naessén T, Krusemo UB, Bergström R. Fracture of the distal forearm as a forecaster of subsequent hip fracture: a population-based cohort study with 24 years of follow-up. Calcif Tissue Int. 1993;52: Cuddihy MT, Gabriel SE, Crowson CS, O Fallon WM, Melton LJ 3rd. Forearm fractures as predictors of subsequent osteoporotic fractures. Osteoporos Int. 1999; 9: Melton LJ 3rd, Atkinson EJ, Cooper C, O Fallon WM, Riggs BL. Vertebral fractures predict subsequent fractures. Osteoporos Int. 1999;10: Melton LJ 3rd, Ilstrup DM, Beckenbaugh RD, Riggs BL. Hip fracture recurrence: a population-based study. Clin Orthop. 1982;No. 167: American College of Rheumatology Ad Hoc Committee on Glucocorticoid- Induced Osteoporosis. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. Arthritis Rheum. 2001;44: Lauritzen JB, Lund B. Risk of hip fracture after osteoporosis fractures: 451 women with fracture of lumbar spine, olecranon, knee or ankle. Acta Orthop Scand. 1993; 64: Greenfield DM, Eastell R. Risk factors for ankle fracture. Osteoporos Int. 2001; 12: Seeley DG, Kelsey J, Jergas M, Nevitt MC, the Study of Osteoporotic Fractures Research Group. Predictors of ankle and foot fractures in older women. J Bone Miner Res. 1996;11: Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. N Engl J Med. 1998;339: Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures: dosage more important than elimination half-life. Arch Intern Med. 1995;155: Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285: Silverman SL. The clinical consequences of vertebral compression fracture. Bone. 1992;13(suppl 2):S27-S Gehlbach SH, Bigelow C, Heimisdottir M, May S, Walker M, Kirkwood JR. Recognition of vertebral fracture in a clinical setting. Osteoporos Int. 2000;11: Van der Klift M, De Laet CE, McCloskey EV, Hofman A, Pols HA. The incidence of vertebral fractures in men and women: the Rotterdam Study. J Bone Miner Res. 2002;17: Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343: Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85: Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337: Kannus P, Parkkari J, Niemi S, et al. Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med. 2000;343:

One year outcomes and costs following a vertebral fracture

One year outcomes and costs following a vertebral fracture Osteoporos Int (2005) 16: 78 85 DOI 10.1007/s00198-004-1646-x ORIGINAL ARTICLE One year outcomes and costs following a vertebral fracture R. Lindsay Æ R. T. Burge Æ D. M. Strauss Received: 18 June 2003

More information

Osteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made?

Osteoporosis in Men. Until recently, the diagnosis of osteoporosis. A New Type of Patient. Al s case. How is the diagnosis made? A New Type of Patient Rafat Faraawi, MD, FRCP(C), FACP Until recently, the diagnosis of osteoporosis in men was uncommon and, when present, it was typically described as a consequence of secondary causes.

More information

The Impact of Nonhip Nonvertebral Fractures in Elderly Women and Men

The Impact of Nonhip Nonvertebral Fractures in Elderly Women and Men ORIGINAL ARTICLE Endocrine Care The Impact of Nonhip Nonvertebral Fractures in Elderly Women and Men Dana Bliuc, Tuan V. Nguyen, John A. Eisman, and Jacqueline R. Center Osteoporosis and Bone Biology (D.B.,

More information

CAROLYN M. KLOTZBUECHER, PHILIP D. ROSS, PAMELA B. LANDSMAN, THOMAS A. ABBOTT III, and MARC BERGER ABSTRACT

CAROLYN M. KLOTZBUECHER, PHILIP D. ROSS, PAMELA B. LANDSMAN, THOMAS A. ABBOTT III, and MARC BERGER ABSTRACT JOURNAL OF BONE AND MINERAL RESEARCH Volume 15, Number 4, 2000 2000 American Society for Bone and Mineral Research Patients with Prior Fractures Have an Increased Risk of Future Fractures: A Summary of

More information

Increased mortality after fracture of the surgical neck of the humerus: a case-control study of 253 patients with a 12-year follow-up.

Increased mortality after fracture of the surgical neck of the humerus: a case-control study of 253 patients with a 12-year follow-up. Increased mortality after fracture of the surgical neck of the humerus: a case-control study of 253 patients with a 12-year follow-up. Olsson, Christian; Petersson, Claes; Nordquist, Anders Published in:

More information

Postmenopausal osteoporosis is a systemic

Postmenopausal osteoporosis is a systemic OSTEOPOROSIS: HARD FACTS ABOUT BONES Steven T. Harris, MD, FACP* ABSTRACT As a consequence of the aging process, osteoporosis affects all men and women. Agerelated loss of bone mass leads to skeletal fragility

More information

The Significance of Vertebral Fractures

The Significance of Vertebral Fractures Special Report The Significance of Vertebral Fractures Both the prevalence and the clinical significance of vertebral fractures has been greatly underestimated by physicians. Vertebral fractures are much

More information

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study Rheumatol Int (2006) 26: 427 431 DOI 10.1007/s00296-005-0004-4 ORIGINAL ARTICLE J. D. Ringe Æ H. Faber Æ P. Farahmand Æ A. Dorst Efficacy of risedronate in men with primary and secondary osteoporosis:

More information

Skeletal Manifestations

Skeletal Manifestations Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes

More information

ORIGINAL ARTICLE. E. Barrett-Connor & S. G. Sajjan & E. S. Siris & P. D. Miller & Y.-T. Chen & L. E. Markson

ORIGINAL ARTICLE. E. Barrett-Connor & S. G. Sajjan & E. S. Siris & P. D. Miller & Y.-T. Chen & L. E. Markson Osteoporos Int (2008) 19:607 613 DOI 10.1007/s00198-007-0508-8 ORIGINAL ARTICLE Wrist fracture as a predictor of future fractures in younger versus older postmenopausal women: results from the National

More information

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one

More information

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone

More information

ORIGINAL INVESTIGATION. Continuously Increasing Number and Incidence of Fall-Induced, Fracture-Associated, spinal cord injuries in older persons

ORIGINAL INVESTIGATION. Continuously Increasing Number and Incidence of Fall-Induced, Fracture-Associated, spinal cord injuries in older persons ORIGINAL INVESTIGATION Continuously Increasing Number and of Fall-Induced, Fracture-Associated, Spinal Cord Injuries in Elderly Persons Pekka Kannus, MD, PhD; Seppo Niemi; Mika Palvanen, MD; Jari Parkkari,

More information

Risedronate prevents hip fractures, but who should get therapy?

Risedronate prevents hip fractures, but who should get therapy? INTERPRETING KEY TRIALS CHAD L. DEAL, MD Head, Center for Osteoporosis and Metabolic Bone Disease, Department of Rheumatic and Immunologic Diseases, The Cleveland Clinic THE HIP TRIAL Risedronate prevents

More information

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS 4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending

More information

Submission to the National Institute for Clinical Excellence on

Submission to the National Institute for Clinical Excellence on Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology

More information

ORIGINAL INVESTIGATION. Low Frequency of Treatment of Osteoporosis Among Postmenopausal Women Following a Fracture. and progressive condition

ORIGINAL INVESTIGATION. Low Frequency of Treatment of Osteoporosis Among Postmenopausal Women Following a Fracture. and progressive condition ORIGINAL INVESTIGATION Low Frequency of Treatment of Osteoporosis Among Postmenopausal Women Following a Fracture Susan E. Andrade, ScD; Sumit R. Majumdar, MD, MPH; K. Arnold Chan, MD, ScD; Diana S. M.

More information

An audit of osteoporotic patients in an Australian general practice

An audit of osteoporotic patients in an Australian general practice professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to

More information

The NOF & NBHA Quality Improvement Registry

The NOF & NBHA Quality Improvement Registry In collaboration with CECity The NOF & NBHA Quality Improvement Registry This registry is approved by CMS as a Qualified Clinical Data Registry (QCDR) for Eligible Professionals and GPRO Practices for

More information

Osteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC.

Osteoporosis: Not Just for Women Anymore. Osteoporosis is characterized by low bone. By Lisanne G. Laurier, MD, PhD, FRCPC. Focus on CME at the University of Western Ontario Osteoporosis: Not Just for Women Anymore By Lisanne G. Laurier, MD, PhD, FRCPC Osteoporosis is characterized by low bone mass and microarchitectural deterioration

More information

Can we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous

Can we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous Can we improve the compliance to prevention treatment after a wrist fracture? Roy Kessous Distal radius fracture in women after menopause is in many cases a first clinical indication for the presence of

More information

Male osteoporosis: clinical approach and management in family practice

Male osteoporosis: clinical approach and management in family practice Singapore Med J 2014; 55(7): 353-357 doi: 10.11622/smedj.2014085 CMEArticle Male osteoporosis: clinical approach and management in family practice Lay Hoon Goh 1,2, MMed, FCFP, Choon How How 1, MMed, FCFP,

More information

Osteoporosis/Fracture Prevention

Osteoporosis/Fracture Prevention Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team

More information

July 2012 CME (35 minutes) 7/12/2016

July 2012 CME (35 minutes) 7/12/2016 Financial Disclosures Epidemiology and Consequences of Fractures Advisory Board: Amgen Janssen Pharmaceuticals Inc. Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Osteoporotic

More information

Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women

Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women Osteoporos Int (2011) 22:2365 2371 DOI 10.1007/s00198-010-1452-6 ORIGINAL ARTICLE Prevalence of vertebral fractures on chest radiographs of elderly African American and Caucasian women D. Lansdown & B.

More information

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security

More information

ASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction

ASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction Asian Spine Journal Asian Spine Clinical Journal Study Asian Spine J 2014;8(6):729-734 High http://dx.doi.org/10.4184/asj.2014.8.6.729 risk patients with osteopenia How Many High Risk Korean Patients with

More information

The Result of the treatment in osteoporotic ankle fractures with small fragment using claw plate in elderly

The Result of the treatment in osteoporotic ankle fractures with small fragment using claw plate in elderly The Result of the treatment in osteoporotic ankle fractures with small fragment using claw plate in elderly Jun-Beom Kim M.D, Byeong-Seop Park M.D, Chi-Hun, Ahn M.D Foot and Ankle Clinics, Department of

More information

Disclosures Fractures:

Disclosures Fractures: Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Research Funding: GlaxoSmithKline, Merck Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Fracture incidence

More information

OSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC

OSTEOPOROSIS MANAGEMENT AND INVESTIGATION. David A. Hanley, MD, FRCPC OSTEOPOROSIS MANAGEMENT AND INVESTIGATION David A. Hanley, MD, FRCPC There is a huge care gap in the management of osteoporosis in this country. As yet unpublished findings from the Canadian Multicentre

More information

The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks

The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks Volume ** Number ** ** VALUE IN HEALTH The Cost-Effectiveness of Bisphosphonates in Postmenopausal Women Based on Individual Long-Term Fracture Risks Tjeerd-Peter van Staa, MD, MA, PhD, 1,2 John A. Kanis,

More information

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,

More information

Assessment of Individual Fracture Risk: FRAX and Beyond

Assessment of Individual Fracture Risk: FRAX and Beyond Curr Osteoporos Rep (2010) 8:131 137 DOI 10.1007/s11914-010-0022-3 Assessment of Individual Fracture Risk: FRAX and Beyond Joop P. W. van den Bergh & Tineke A. C. M. van Geel & Willem F. Lems & Piet P.

More information

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014 Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis

More information

Osteoporosis International. Original Article. Bone Mineral Density and Vertebral Fractures in Men

Osteoporosis International. Original Article. Bone Mineral Density and Vertebral Fractures in Men Osteoporos Int (1999) 10:265 270 ß 1999 International Osteoporosis Foundation and National Osteoporosis Foundation Osteoporosis International Original Article Bone Mineral Density and Vertebral Fractures

More information

An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines

An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines Osteoporos Int (2006) 17: 1111 1115 DOI 10.1007/s00198-006-0101-6 SHORT COMMUNICATION An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines R. Baddoura. H. Awada. J. Okais.

More information

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary

Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary Parathyroid Hormone Analog for Osteoporosis Prior Authorization with Quantity Limit Criteria Program Summary This prior authorization program applies to Commercial, NetResults A series, NetResults F series

More information

PHC4 Issue Brief. Osteoporosis Facts and Figures. November 19, 1997

PHC4 Issue Brief. Osteoporosis Facts and Figures. November 19, 1997 PHC4 Issue Brief Osteoporosis Facts and Figures November 19, 1997 Background Information: Osteoporosis is a disease characterized by low bone mass and structural deterioration of bone tissue, leading to

More information

Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures

Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures DOI 10.1007/s00198-013-2460-0 ORIGINAL ARTICLE Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures H. Johansson & A. Odén & E. V. McCloskey & J. A. Kanis Received:

More information

Using the FRAX Tool. Osteoporosis Definition

Using the FRAX Tool. Osteoporosis Definition How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX

More information

Men and Osteoporosis So you think that it can t happen to you

Men and Osteoporosis So you think that it can t happen to you Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School

More information

Forteo (teriparatide) Prior Authorization Program Summary

Forteo (teriparatide) Prior Authorization Program Summary Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis

More information

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO

OSTEOPOROSIS IN MEN. Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO OSTEOPOROSIS IN MEN Nelson B. Watts, MD OSTEOPOROSIS AND BONE HEALTH SERVICES CINCINNATI, OHIO DISCLOSURES Speakers Bureau: Amgen, Radius Consultant: Abbvie, Amgen, Janssen, Radius, Sanofi Watts NB et

More information

Fractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases

Fractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases Financial Disclosures Fractures: Epidemiology and Risk Factors Research grants, speaking or consulting: Amgen, Lilly, Merck, Novartis, Radius Dennis M. Black, PhD Department of Epidemiology and Biostatistics

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s

More information

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage

More information

Differentiating Pharmacological Therapies for Osteoporosis

Differentiating Pharmacological Therapies for Osteoporosis Differentiating Pharmacological Therapies for Osteoporosis Socrates E Papapoulos Department of Endocrinology & Metabolic Diseases Leiden University Medical Center The Netherlands Competing interests: consulting/speaking

More information

Factors associated with diagnosis and treatment of osteoporosis in older adults

Factors associated with diagnosis and treatment of osteoporosis in older adults Osteoporos Int (2009) 20:1963 1967 DOI 10.1007/s00198-008-0831-8 SHORT COMMUNICATION Factors associated with diagnosis and treatment of osteoporosis in older adults S. Nayak & M. S. Roberts & S. L. Greenspan

More information

Incidence and Mortality after Proximal Humerus Fractures Over 50 Years of Age in South Korea: National Claim Data from 2008 to 2012

Incidence and Mortality after Proximal Humerus Fractures Over 50 Years of Age in South Korea: National Claim Data from 2008 to 2012 J Bone Metab 2015;22:17-21 http://dx.doi.org/10.11005/jbm.2015.22.1.17 pissn 2287-6375 eissn 2287-7029 Original Article Incidence and Mortality after Proximal Humerus Fractures Over 50 s of Age in South

More information

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care

AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee

More information

Distal Radius Fracture Risk Reduction With a Comprehensive Osteoporosis Management Program

Distal Radius Fracture Risk Reduction With a Comprehensive Osteoporosis Management Program SCIENTIFIC ARTICLE Distal Radius Fracture Risk Reduction With a Comprehensive Osteoporosis Management Program Neil G. Harness, MD, Tadashi Funahashi, MD, Richard Dell, MD, Annette L. Adams, PhD, MPH, Raoul

More information

Current Issues in Osteoporosis

Current Issues in Osteoporosis Current Issues in Osteoporosis California AACE 18TH Annual Meeting & Symposium Marina del Rey, CA September 15, 2018 Michael R. McClung, MD, FACP,FACE Director, Oregon Osteoporosis Center Portland, Oregon,

More information

Direct healthcare costs of hip, vertebral, and nonhip, non-vertebral fractures.

Direct healthcare costs of hip, vertebral, and nonhip, non-vertebral fractures. Thomas Jefferson University Jefferson Digital Commons College of Population Health Faculty Papers Jefferson College of Population Health 12-1-2009 Direct healthcare costs of hip, vertebral, and nonhip,

More information

Fracture Prediction From Bone Mineral Density in Japanese Men and Women ABSTRACT

Fracture Prediction From Bone Mineral Density in Japanese Men and Women ABSTRACT JOURNAL OF BONE AND MINERAL RESEARCH Volume 18, Number 8, 2003 2003 American Society for Bone and Mineral Research Fracture Prediction From Bone Mineral Density in Japanese Men and Women SAEKO FUJIWARA,

More information

Healthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C

Healthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C Healthy Bones: Osteoporosis Management Laurel Short, MSN, FNP-C Disclosure I have no current affiliation or financial interest with any grantor or commercial interests that may have direct interest in

More information

How to start and expand Fracture Liaison Services

How to start and expand Fracture Liaison Services How to start and expand Fracture Liaison Services The International Osteoporosis Foundation (IOF) Capture the Fracture Campaign has recognized that development of Fracture Liaison Services (FLS) may occur

More information

Analysis of Clinical Features of Hip Fracture Patients with or without Prior Osteoporotic Spinal Compression Fractures

Analysis of Clinical Features of Hip Fracture Patients with or without Prior Osteoporotic Spinal Compression Fractures J Bone Metab 2013;20:11-15 http://dx.doi.org/10.11005/jbm.2013.20.1.11 pissn 2287-6375 eissn 2287-7029 Original Article Analysis of Clinical Features of Hip Fracture Patients with or without Prior Osteoporotic

More information

BONIVA (ibandronate sodium)

BONIVA (ibandronate sodium) BONIVA (ibandronate sodium) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices

More information

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology

More information

Controversies in Osteoporosis Management

Controversies in Osteoporosis Management Controversies in Osteoporosis Management 2018 Northwest Rheumatism Society Meeting Portland, OR April 28, 2018 Michael R. McClung, MD, FACP Director, Oregon Osteoporosis Center Portland, Oregon, USA Institute

More information

Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA

Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA ORIGINAL ARTICLE Comparison of Bone Density of Distal Radius With Hip and Spine Using DXA Leila Amiri 1, Azita Kheiltash 2, Shafieh Movassaghi 1, Maryam Moghaddassi 1, and Leila Seddigh 2 1 Rheumatology

More information

Appendix G How to start and expand Fracture Liaison Services

Appendix G How to start and expand Fracture Liaison Services 1 Appendix G How to start and expand Fracture Liaison Services The International Osteoporosis Foundation (IOF) Capture the Fracture Campaign has recognized that development of Fracture Liaison Services

More information

Challenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA

Challenging the Current Osteoporosis Guidelines. Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Challenging the Current Osteoporosis Guidelines Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Whom to screen Which test How to diagnose Whom to treat Benefits

More information

Collagen Crosslinks, Any Method

Collagen Crosslinks, Any Method 190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement

More information

Osteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009

Osteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009 American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium

More information

INHALED AND NASAL CORTICOSTEROID USE AND THE RISK OF FRACTURE. Online data supplement.

INHALED AND NASAL CORTICOSTEROID USE AND THE RISK OF FRACTURE. Online data supplement. INHALED AND NASAL CORTICOSTEROID USE AND THE RISK OF FRACTURE. Online data supplement. Samy Suissa, PhD, Marc Baltzan, MD, MSc, Richard Kremer, MD, Pierre Ernst, MD, MSc 26 METHODS Source of data We used

More information

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329

Horizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329 Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature

More information

FORTEO (teriparatide) INJECTION

FORTEO (teriparatide) INJECTION FORTEO (teriparatide) INJECTION Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage

More information

ORIGINAL INVESTIGATION. Bone Mineral Density Measurement and Treatment for Osteoporosis in Older Individuals With Fractures

ORIGINAL INVESTIGATION. Bone Mineral Density Measurement and Treatment for Osteoporosis in Older Individuals With Fractures ORIGINAL INVESTIGATION Bone Mineral Density Measurement and Treatment for Osteoporosis in Older Individuals With Fractures A Gap in Evidence-Based Practice Guideline Implementation Adrianne Feldstein,

More information

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women

More information

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008

BAD TO THE BONE. Peter Jones, Rheumatologist QE Health, Rotorua. GP CME Conference Rotorua, June 2008 BAD TO THE BONE Peter Jones, Rheumatologist QE Health, Rotorua GP CME Conference Rotorua, June 2008 Agenda Osteoporosis in Men Vitamin D and Calcium Long-term treatment with Bisphosphonates Pathophysiology

More information

Tymlos (abaloparatide)

Tymlos (abaloparatide) Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos

More information

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre

Horizon Scanning Technology Briefing. Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal. National Horizon Scanning Centre Horizon Scanning Technology Briefing National Horizon Scanning Centre Zoledronic Acid (Aclasta) once yearly treatment for postmenopausal osteoporosis December 2006 This technology summary is based on information

More information

Asmall number of studies have examined

Asmall number of studies have examined Appendix B: Evidence on Hormone Replacement Therapy and Fractures B Asmall number of studies have examined directly the relationship between use of hormonal replacement therapy and risk of hip fracture

More information

Tamer Mettyas 1* and Clare Carpenter 2

Tamer Mettyas 1* and Clare Carpenter 2 Mettyas and Carpenter Journal of Orthopaedic Surgery and Research 2013, 8:44 RESEARCH ARTICLE Open Access Secondary prevention of osteoporosis in non-neck of femur fragility : is it value for money? A

More information

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S

The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden Willis M S Record Status This is a critical abstract of an economic evaluation that meets the criteria

More information

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis

More information

Collagen Crosslinks, Any Method

Collagen Crosslinks, Any Method 190.19 - Collagen Crosslinks, Any Method Collagen crosslinks, part of the matrix of bone upon which bone mineral is deposited, are biochemical markers the excretion of which provides a quantitative measurement

More information

Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis?

Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis? ORIGINAL ARTICLE Korean J Intern Med 2014;29:509-515 Are glucocorticoid-induced osteoporosis recommendations sufficient to determine antiosteoporotic treatment for patients with rheumatoid arthritis? Joo-Hyun

More information

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against

This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against This house believes that HRT should be the first-line prevention for postmenopausal osteoporosis: the case against Juliet Compston Professor of Bone Medicine University of Cambridge School of Clinical

More information

The Effect of Disc Degeneration in Osteoporotic Vertebral Fracture

The Effect of Disc Degeneration in Osteoporotic Vertebral Fracture Abstract The Effect of Disc Degeneration in Osteoporotic Vertebral Fracture Kyu Sung Lee, MD Department of Orthopaedic Surgery, Pochun Joongmoon Medical School Study design : Radiographic findings of vertebral

More information

Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck

Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Fracture incidence and impact of fractures

More information

A response by Servier to the Statement of Reasons provided by NICE

A response by Servier to the Statement of Reasons provided by NICE A response by Servier to the Statement of Reasons provided by NICE Servier gratefully acknowledges the Statement of Reasons document from NICE, and is pleased to provide information to assist NICE in its

More information

BEST PRACTICE FRAMEWORK QUESTIONNAIRE

BEST PRACTICE FRAMEWORK QUESTIONNAIRE CAPTURE the FRACTURE BEST PRACTICE FRAMEWORK QUESTIONNAIRE INTRODUCTION Capture the Fracture invites Fracture Liaison Services (FLS) to apply for Capture the Fracture Best Practice Recognition programme.

More information

Prevention of Osteoporotic Hip Fracture

Prevention of Osteoporotic Hip Fracture Prevention of Osteoporotic Hip Fracture Dr Law Sheung Wai 8th July 2007 Associate Consultant Spine team / Orthopedic Rehabilitation Department of Orthopedics and Traumatology NTE Cluster 1 Objectives Problems

More information

Fracture=Bone Attack:

Fracture=Bone Attack: Fracture=Bone Attack: Linking Hip Fractures to Osteoporosis Care Angela M. Cheung, MD, PhD, FRCPC Professor of Medicine, University of Toronto Potential Conflicts of Interests Industry Grants (to UHN)

More information

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464

Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 Bisphosphonates for treating osteoporosis Technology appraisal guidance Published: 9 August 2017 nice.org.uk/guidance/ta464 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

What is Osteoporosis?

What is Osteoporosis? What is Osteoporosis? 2000 NIH Definition A skeletal disorder characterized by compromised bone strength predisposing a person to an increased risk of fracture. Bone strength reflects the integration of

More information

Technical Report FORCE ATTENUATION CHARACTERISTICS OF DIFFERENT FORCE ABSORBING MATERIALS USED IN A HIP PROTECTOR FOR THE ELDERLY

Technical Report FORCE ATTENUATION CHARACTERISTICS OF DIFFERENT FORCE ABSORBING MATERIALS USED IN A HIP PROTECTOR FOR THE ELDERLY Technical Report FORCE ATTENUATION CHARACTERISTICS OF DIFFERENT FORCE ABSORBING MATERIALS USED IN A HIP PROTECTOR FOR THE ELDERLY December, 2005 by John W. Chow, Ph.D. Associate Professor Mark D. Tillman,

More information

Setting The setting was primary care. The economic study was carried out in the USA.

Setting The setting was primary care. The economic study was carried out in the USA. Universal bone densitometry screening combined with alendronate therapy for those diagnosed with osteoporosis is highly cost-effective for elderly women Schousboe J T, Ensrud K E, Nyman J A, Melton L J,

More information

Secondary and tertiary prevention in the management of low-trauma fracture

Secondary and tertiary prevention in the management of low-trauma fracture Secondary and tertiary prevention in the management of low-trauma fracture Tenielle A Myers and N Kathryn Briffa Curtin University of Technology, Perth A significant risk factor for osteoporotic fracture

More information

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018 Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy

More information

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence

Overview. Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases. People Centred Positive Compassion Excellence Overview Osteoporosis and Metabolic Bone Disease Dr Chandini Rao Consultant Rheumatologist Bone Biology Osteoporosis Osteomalacia Paget s Disease Cases Bone Biology Osteoporosis Increased bone remodelling

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 21 July 2010 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 21 July 2010 ACTONEL 5 mg, film-coated tablet B/14 (CIP code: 354 362-3) ACTONEL 30 mg, film-coated tablet B/28 (CIP

More information

Summary. Background. Diagnosis

Summary. Background. Diagnosis March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.

More information

Outline Vertebroplasty and Kyphoplasty: Who, What, and When

Outline Vertebroplasty and Kyphoplasty: Who, What, and When Outline Vertebroplasty and Kyphoplasty: Who, What, and When Douglas C. Bauer, MD University of California San Francisco, USA Vertebral fracture epidemiology, consequences and diagnosis Kyphoplasty and

More information

Dual-energy Vertebral Assessment

Dual-energy Vertebral Assessment Dual-energy Vertebral Assessment gehealthcare.com Dual-energy Vertebral Assessment More than 40% of women with normal or osteopenic BMD had a moderate or severe vertebral deformation seen with DVA. Patrick

More information